Comparing blood tests for leftover cancer DNA in advanced non small cell lung cancer
Compares blood tests that detect leftover tumor DNA in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Key facts
- Where
- Groningen, Scheemda, and Zwolle, NetherlandsSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III non-small cell lung cancer who are planned for treatment meant to remove all of the disease, with surgery and/or radiotherapy. Blood samples will be tested for tumor DNA.
- Age
- 18 years or older.
- Sex
- Men and women can join.
- Disease stage
- Non-small cell lung cancer, clinical tumor stage III (cT1-4, cN0-3, M0).
- Earlier treatment
- Must be scheduled for treatment meant to remove all of the disease (surgery and/or radiotherapy).
- Biomarker or test result
- Enough tumor material is needed (at least 50ng tumor DNA, FFPE), either before or after surgery.
Main reasons for not taking part
- Distant metastases confirmed.
- Non-small cell lung cancer together with another cancer at the same time (skin cancer other than melanoma is allowed).
- Other cancers (skin cancer other than melanoma, or cancers treated successfully with more than 5 years of follow-up without return, are allowed).
- Unlikely to follow the study plan or complete the study.
- No tumor tissue sample available, or tumor content in the sample below 20%.
Read by machine on 12 November 2026.
Where in Netherlands
- University Medical Center Groningen, Departments of Pulmonology and PathologyGroningen, NetherlandsContact: T.Jeroen Hiltermann, MDTaking people
- Ommelander Ziekenhuis GroningenScheemda, NetherlandsContact: Remge Pieterman, MDTaking people
- IsalaZwolle, NetherlandsContact: Peter Plomp, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Medical Center Groningen
- Trial code
- NCT06111807
- Record updated
- 30 March 2025
- Original description
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough.Read full original descriptionShow less
GUIding Multi-moDal thErapies Against MRD by LiquidBiopsies in Non Small Cell Lung Cancer- GUIDE.MRD-03-NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough.
There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.
The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.
GUIDE.MRD-03-NSCLC is a part of the GUIDE.MRD project.
Inclusion: NSCLC, clinical tumor stage III (cT1-4, cN0-3, M0); Patient 18 years or older; Scheduled for curative intent treatment (surgery and/or radiotherapy); Patient able to understand and sign written informed consent; Baseline contrast enhanced CT thorax abdomen (or PET/CT), MRI (or CT) brain, Pulmonary function tests (at least FEV1 and DLCO/KCO); Ability to obtain sufficient tumor material (≥50ng tumor DNA, FFPE ). Either at baseline or after surgery.
Exclusion: With synchronous NSCLC cancer and non-NSCLC cancer (except skin cancer other than melanoma); With other cancers (excluding NSCLC or skin cancer other than melanoma, or cancers treated curatively with follow up of more than 5 years without recurrence); Verified distant metastases; Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study; No tissue sample available for the project, or tumor content in the tissue sample is <20%.